Kumai Y, Miyamoto T, Mastsubara K, et al. Assessment of oropharyngeal swallowing dysfunction in myasthenia gravis patients presenting with difficulty in swallowing. Auris Nasus Larynx . 2019;46(3 ...

AstraZeneca said on Thursday its experimental therapy, gefurulimab, met the primary goal and all secondary endpoints in a ...

Chatterjee T, Senthil Kumaran S, Roy M. A case report and literature review of new-onset myasthenia gravis after COVID-19 infection. Cureus. Published online December 28, 2022. doi:10.7759/cureus ...

Three patients with no prior neurologic or autoimmune disorders developed myasthenia gravis within a week after onset ... for 7 days. On day 7, he developed muscle fatigue, diplopia, and dysphagia.

Patients with myasthenia gravis suffer from muscle weakness that can affect daily activities including eye movement, facial expression, chewing, talking and swallowing.

Myasthenia gravis, or MG, is "a chronic autoimmune neuromuscular disorder that causes muscle weakness and fatigue," says Hesterlee. It occurs "when a person’s immune system is essentially ...

Myasthenia gravis physical exam findings 1-4,6,7,13 Ocular – 50% to 60% present with ocular ­complaints; about half of these patients will develop generalized disease within two years.

Myasthenia gravis, an autoimmune neurologic disorder, ... The third patient developed dysphagia and respiratory failure and was transferred to the ICU for mechanical ventilation.

Immune checkpoints could be key to treating autoimmune disease myasthenia gravis Date: November 30, 2018 Source: Kanazawa University Summary: The PD-1 immune checkpoint is essential for self ...

The RAISE trial was led by James Howard, MD, professor of neurology at the UNC School of Medicine. Generalized myasthenia gravis is a rare, chronic, and unpredictable auto-immune disease ...

And anyone who suffers from myasthenia gravis, however mild it is, should be monitored, ... who has trouble swallowing, if they're coming up against a wall with their physician, ...

The US Food and Drug Administration (FDA) has approved zilucoplan (Zilbrysq, UCB) for the treatment of generalized myasthenia gravis (gMG) in adults who are antiacetylcholine receptor (AChR ...